▴ 90Yttrium (90Y) ibritumomab tiuxetan is a radiolabeled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumor activity as a result of emission of β particles. It is administered as part of a therapeutic regimen which includes rituximab, a monoclonal antibody which produces antibody-dependent cell-and complement-mediated cytotoxicity.
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012